SAN DIEGO, May 25, 2017 /PRNewswire/ -- CureMatch™ today announced the pricing for its Personalized Combination Therapy™ report. The report guides oncologists in the selection of cancer treatment options that are personalized for individual patients, using supercomputing and the latest advances in genomics.
"We want all cancer patients to get the benefit of personalized medicine and combination therapy," said Blaise Barrelet, cancer survivor and CEO of CureMatch. "That's why we are offering it at an affordable price."
The cost of the CureMatch report is $1000. The price of the report is free for children with cancer.
"I have four children, and children are the ones with the most life to lose," added Blaise Barrelet. "Pediatric cancer is devastating. When a kid has cancer, it's like the whole family has cancer. We don't want these families to struggle financially, so we are offering our report to them at no cost."
Personalized cancer treatment starts with genomic testing of the tumor. Genomic testing is not performed by CureMatch, but by one of many 3rd party companies. CureMatch uses the genomic data in its analysis, and then guides the oncologist so that they can combine drugs together in the right way to best fight the cancer. Typically, the cost of genomic testing is mostly covered by insurance.
"Genomic testing opens the door to cutting-edge treatment possibilities for cancer patients, and the CureMatch report provides oncologists with actionable knowledge and insight to guide them to treat their patients effectively," continued Blaise Barrelet. "We think the combined cost of the genomic testing and our report should stay between $1500 and $2000."
The CureMatch report is available for patients of all ages, with all types of cancer, at all stages of the disease, and at any time during the treatment course. Patients or their families can learn more at www.curematch.com.
CureMatch™, Inc., based in San Diego, is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS, and is considered by many to be the future of cancer treatment. CureMatch's report guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient's own tumor. The CureMatch technology has a foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/curematch-announces-pricing-for-its-cutting-edge-combination-therapy-report-for-cancer-treatment-300463713.html